Will allogeneic CAR T cells for CD19⁺ malignancies take autologous CAR T cells 'off the shelf'?

Amanda M DiNofia^{1

2}, Stephan A Grupp^{3

4}

Affiliations

¹ Cancer Immunotherapy Program, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
² Division of Oncology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Cancer Immunotherapy Program, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA, USA. grupp@chop.edu.
⁴ Division of Oncology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. grupp@chop.edu.

Comment

Amanda M DiNofia et al. Nat Rev Clin Oncol. 2021 Apr.

. 2021 Apr;18(4):195-196.

doi: 10.1038/s41571-021-00485-1.

Amanda M DiNofia^{1

2}, Stephan A Grupp^{3

4}

¹ Cancer Immunotherapy Program, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
² Division of Oncology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
³ Cancer Immunotherapy Program, Cellular Therapy and Transplant Section, Children's Hospital of Philadelphia, Philadelphia, PA, USA. grupp@chop.edu.
⁴ Division of Oncology, Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. grupp@chop.edu.

No abstract available

Comment on

Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar OC, Lucchini G, Pinner D, Jain N, Kantarjian H, Boissel N, Maus MV, Frigault MJ, Baruchel A, Mohty M, Gianella-Borradori A, Binlich F, Balandraud S, Vitry F, Thomas E, Philippe A, Fouliard S, Dupouy S, Marchiq I, Almena-Carrasco M, Ferry N, Arnould S, Konto C, Veys P, Qasim W; UCART19 Group. Benjamin R, et al. Lancet. 2020 Dec 12;396(10266):1885-1894. doi: 10.1016/S0140-6736(20)32334-5. Lancet. 2020. PMID: 33308471 Free PMC article. Clinical Trial.

1. Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018). - DOI
1. Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017). - DOI
1. Pasquini, M. C. et al. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Adv. 4, 5414–5424 (2020). - DOI
1. Depil, S., Duchateau, P., Grupp, S. A., Mufti, G. & Poirot, L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat. Rev. Drug Discov. 19, 185–199 (2020). - DOI
1. Benjamin, R. et al. Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet 396, 1885–1894 (2020). - DOI